Trial Profile
A Phase II Study to Assess the Efficacy and Safety of Preoperative Chemotherapy With Radiation Therapy for Patients With Borderline Unresectable Adenocarcinoma of the Pancreas
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2019
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 21 Nov 2019 Status changed from active, no longer recruiting to discontinued.
- 17 Apr 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.
- 11 Apr 2018 Planned End Date changed from 1 Mar 2019 to 1 Mar 2020.